Mitoxantrone Hydrochloride

Acute Lymphoblastic Leukemia, Advance Directives, Hodgkin's Lymphoma + 12 more
Treatment
9 FDA approvals
20 Active Studies for Mitoxantrone Hydrochloride

What is Mitoxantrone Hydrochloride

MitoxantroneThe Generic name of this drug
Treatment SummaryAn antineoplastic agent derived from anthracenedione, a type of chemical compound.
Novantroneis the brand name
Mitoxantrone Hydrochloride Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Novantrone
Mitoxantrone
1987
12

Approved as Treatment by the FDA

Mitoxantrone, otherwise known as Novantrone, is approved by the FDA for 9 uses which include Acute Myeloid Leukemia and Advance Directives .
Acute Myeloid Leukemia
Used to treat Acute Myeloid Leukemia (AML) in combination with null
Advance Directives
Multiple Sclerosis
Helps manage Secondary Progressive Multiple Sclerosis (SPMS)
Multiple Sclerosis
Helps manage Progressive Relapsing Multiple Sclerosis
Relapsed Lymphomas
Relapsing Remitting Multiple Sclerosis
Helps manage Relapsing Remitting Multiple Sclerosis (RRMS)
Liver carcinoma
Relapsed Leukemia
Metastatic Breast Cancer

Effectiveness

How Mitoxantrone Hydrochloride Affects PatientsIn laboratory tests, mitoxantrone has been found to stop the growth of B cells, T cells, and macrophages and reduce the activity of certain proteins involved in immunity. It also reduces the amount of interferon gamma, TNFa, and IL-2 that are released from these cells.
How Mitoxantrone Hydrochloride works in the bodyMitoxantrone works by binding to DNA and interfering with the repair process. It binds to DNA, preventing the enzyme responsible for fixing DNA from doing its job. This stops the cell from being able to fix itself, leading to cell death. It affects both growing and inactive cells, so it is not specific to any particular stage of the cell cycle.

When to interrupt dosage

The amount of Mitoxantrone Hydrochloride is contingent upon the diagnosed state, including Metastatic Breast Cancer, Acute Promyelocytic Leukemia and Advance Directives. The dosage fluctuates as per the route of administration (e.g. Liquid or Injection, solution, concentrate) specified in the table hereunder.
Condition
Dosage
Administration
Advance Directives
2.0 mg/mL, , 2.5 mg/mL, 3.0 mg/mL
Liquid, Injection, solution, concentrate, Injection, solution, , Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Solution - Intravenous, Liquid - Intravenous, Solution, Intravenous
Hodgkin's Lymphoma
2.0 mg/mL, , 2.5 mg/mL, 3.0 mg/mL
Liquid, Injection, solution, concentrate, Injection, solution, , Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Solution - Intravenous, Liquid - Intravenous, Solution, Intravenous
Multiple Sclerosis
2.0 mg/mL, , 2.5 mg/mL, 3.0 mg/mL
Liquid, Injection, solution, concentrate, Injection, solution, , Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Solution - Intravenous, Liquid - Intravenous, Solution, Intravenous
Acute Promyelocytic Leukemia
2.0 mg/mL, , 2.5 mg/mL, 3.0 mg/mL
Liquid, Injection, solution, concentrate, Injection, solution, , Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Solution - Intravenous, Liquid - Intravenous, Solution, Intravenous
Metastatic Breast Cancer
2.0 mg/mL, , 2.5 mg/mL, 3.0 mg/mL
Liquid, Injection, solution, concentrate, Injection, solution, , Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Solution - Intravenous, Liquid - Intravenous, Solution, Intravenous
Non-Hodgkin's Lymphoma
2.0 mg/mL, , 2.5 mg/mL, 3.0 mg/mL
Liquid, Injection, solution, concentrate, Injection, solution, , Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Solution - Intravenous, Liquid - Intravenous, Solution, Intravenous
Relapsed Lymphomas
2.0 mg/mL, , 2.5 mg/mL, 3.0 mg/mL
Liquid, Injection, solution, concentrate, Injection, solution, , Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Solution - Intravenous, Liquid - Intravenous, Solution, Intravenous
Acute Myeloid Leukemia
2.0 mg/mL, , 2.5 mg/mL, 3.0 mg/mL
Liquid, Injection, solution, concentrate, Injection, solution, , Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Solution - Intravenous, Liquid - Intravenous, Solution, Intravenous
Relapsed Leukemia
2.0 mg/mL, , 2.5 mg/mL, 3.0 mg/mL
Liquid, Injection, solution, concentrate, Injection, solution, , Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Solution - Intravenous, Liquid - Intravenous, Solution, Intravenous
Liver carcinoma
2.0 mg/mL, , 2.5 mg/mL, 3.0 mg/mL
Liquid, Injection, solution, concentrate, Injection, solution, , Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Solution - Intravenous, Liquid - Intravenous, Solution, Intravenous
Hematopoietic stem cells
2.0 mg/mL, , 2.5 mg/mL, 3.0 mg/mL
Liquid, Injection, solution, concentrate, Injection, solution, , Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Solution - Intravenous, Liquid - Intravenous, Solution, Intravenous
Acute Lymphoblastic Leukemia
2.0 mg/mL, , 2.5 mg/mL, 3.0 mg/mL
Liquid, Injection, solution, concentrate, Injection, solution, , Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Solution - Intravenous, Liquid - Intravenous, Solution, Intravenous
Relapsing Remitting Multiple Sclerosis
2.0 mg/mL, , 2.5 mg/mL, 3.0 mg/mL
Liquid, Injection, solution, concentrate, Injection, solution, , Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Solution - Intravenous, Liquid - Intravenous, Solution, Intravenous
Hemopoietic stem cell transplant
2.0 mg/mL, , 2.5 mg/mL, 3.0 mg/mL
Liquid, Injection, solution, concentrate, Injection, solution, , Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Solution - Intravenous, Liquid - Intravenous, Solution, Intravenous
Multiple Sclerosis
2.0 mg/mL, , 2.5 mg/mL, 3.0 mg/mL
Liquid, Injection, solution, concentrate, Injection, solution, , Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Solution - Intravenous, Liquid - Intravenous, Solution, Intravenous

Warnings

There are 20 known major drug interactions with Mitoxantrone Hydrochloride.
Common Mitoxantrone Hydrochloride Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Mitoxantrone is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Mitoxantrone is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Acteoside.
Mitoxantrone Hydrochloride Toxicity & Overdose RiskAn overdose on this drug can cause a severe decrease in white blood cells, which can lead to an increased risk of infection.

Mitoxantrone Hydrochloride Novel Uses: Which Conditions Have a Clinical Trial Featuring Mitoxantrone Hydrochloride?

Presently, 785 active studies are being conducted to examine the efficacy of Mitoxantrone Hydrochloride in treating Hodgkin's Lymphoma, Metastatic Breast Cancer and Relapsed Lymphomas.
Condition
Clinical Trials
Trial Phases
Acute Lymphoblastic Leukemia
134 Actively Recruiting
Phase 2, Phase 3, Phase 1, Not Applicable, Early Phase 1
Metastatic Breast Cancer
81 Actively Recruiting
Phase 2, Not Applicable, Phase 3, Phase 1, Phase 4
Liver carcinoma
0 Actively Recruiting
Non-Hodgkin's Lymphoma
171 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1
Hodgkin's Lymphoma
73 Actively Recruiting
Phase 1, Phase 2, Phase 3, Not Applicable
Relapsing Remitting Multiple Sclerosis
12 Actively Recruiting
Not Applicable, Phase 3, Phase 2, Phase 1, Phase 4
Relapsed Lymphomas
0 Actively Recruiting
Multiple Sclerosis
0 Actively Recruiting
Hemopoietic stem cell transplant
0 Actively Recruiting
Acute Myeloid Leukemia
319 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1
Relapsed Leukemia
2 Actively Recruiting
Phase 1
Hematopoietic stem cells
2 Actively Recruiting
Early Phase 1, Phase 1
Multiple Sclerosis
10 Actively Recruiting
Phase 3, Phase 1, Phase 2, Phase 4, Not Applicable, Early Phase 1
Acute Promyelocytic Leukemia
1 Actively Recruiting
Phase 2
Advance Directives
0 Actively Recruiting

Mitoxantrone Hydrochloride Reviews: What are patients saying about Mitoxantrone Hydrochloride?

5Patient Review
6/20/2009
Mitoxantrone Hydrochloride for Multiple Sclerosis Symptoms Return then Become Less Severe
After years of taking Rebif, my neurologist recommended this treatment to me. I was terrified of progressing to advanced RRMS andsecondary progressive MS, but after two years on the chemo with no side effects, my EDSS score went from 4.5 to 2.
3.7Patient Review
5/18/2009
Mitoxantrone Hydrochloride for Pain with Advanced Prostate Cancer Resistant to Hormones

Patient Q&A Section about mitoxantrone hydrochloride

What kind of chemo is mitoxantrone?

"Mitoxantrone is an anti-cancer drug that is classified as an "antitumor antibiotic."" - Anonymous Online Contributor

Unverified Answer

How does mitoxantrone work in the body?

"Mitoxantrone is an injection that falls into the category of medications known as anthracenediones. This particular medication works to treat MS by hindering certain cells of the immune system from being able to reach the brain and spinal cord where they can cause damage. As for cancer, mitoxantrone work by stopping the growth and spread of cancer cells." - Anonymous Online Contributor

Unverified Answer

What is mitoxantrone used for?

"Mitoxantrone injection is a medication used to treat [advanced prostate cancer](https://www.withpower.com/clinical-trials/advanced-prostate-cancer) and acute nonlymphocytic leukemia. It is typically used in conjunction with other medications and belongs to a group of medications known as antineoplastics or cancer medications. Mitoxantrone is also sometimes used to treat multiple sclerosis." - Anonymous Online Contributor

Unverified Answer

How long does mitoxantrone take to work?

"The average response time to mitoxantrone chemotherapy was 21 days, with 7 out of 15 dogs experiencing complete responses that lasted an average of 84 days." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Clinical Trials for Mitoxantrone Hydrochloride

Have you considered Mitoxantrone Hydrochloride clinical trials? We made a collection of clinical trials featuring Mitoxantrone Hydrochloride, we think they might fit your search criteria.
Have you considered Mitoxantrone Hydrochloride clinical trials? We made a collection of clinical trials featuring Mitoxantrone Hydrochloride, we think they might fit your search criteria.
Have you considered Mitoxantrone Hydrochloride clinical trials? We made a collection of clinical trials featuring Mitoxantrone Hydrochloride, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top